Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CODEXIS, INC.CDXS · Entity 6428 | See Remarks | October 12, 2026 | October 14, 2026 |
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | June 12, 2025 | June 13, 2025 |
| Harpoon Therapeutics, Inc.HARP · Entity 11424 | Chief Financial Officer | January 28, 2022 | February 01, 2022 |
| Zosano Pharma CorpZSAN · Entity 12518 | CFO and Chief Business Officer | May 25, 2017 | May 25, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CODEXIS, INC.
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,475 |
Reported balance
After 2026-10-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 6,335 · Balance 60,475 F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to Restricted Stock Units ("RSUs") of the Issuer. F2: Includes 7,707 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to Restricted Stock Units ("RSUs") of the Issuer.
F2: Includes 7,707 restricted stock units.
Coherus Oncology, Inc.
Report date June 12, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2035-06-12 | Direct | 112,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 112,000 · Balance 112,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
Harpoon Therapeutics, Inc.
Report date January 28, 2022 · Filed February 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2032-01-27 | Direct | 115,000 |
Reported balance
After 2022-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-28 · Grant · Acquired 115,000 · Balance 115,000 F1: 1/48th of the total stock option will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 28, 2022, subject to the continuing employment of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total stock option will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 28, 2022, subject to the continuing employment of the Reporting Person on each vesting date.
Zosano Pharma Corp
Report date May 25, 2017 · Filed May 25, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 115,750 |
Reported balance
After 2017-05-25 transaction · row 1
1 source rowRow 1 · 2017-05-25 · Purchase · Acquired 68,000 · Balance 115,750 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.76 · Expires 2031-06-02 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1: The options vest at the rate of 2.778% monthly, beginning on the one-month anniversary of the grant date, with 100% vested on the three-year anniversary of the grant date, subject to the provision of service by the Reporting Person to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest at the rate of 2.778% monthly, beginning on the one-month anniversary of the grant date, with 100% vested on the three-year anniversary of the grant date, subject to the provision of service by the Reporting Person to the Issuer on each vesting date.
F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 14, 2026 21:19 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 6,335 | $1.36 | $8,619.40 |
DisclosureSEC source: 0001610717-26-000438 · form4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,475 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to Restricted Stock Units ("RSUs") of the Issuer. F2 · balance_after: Includes 7,707 restricted stock units. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 00:53 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 316,100 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001610717-26-000071 · form4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,100 Underlying: Common Stock · 316,100 shares Expires 2036-02-23 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 21:07 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 3,826 | $1.31 | $5,000.96 |
DisclosureSEC source: 0001610717-26-000046 · form4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,810 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to Restricted Stock Units ("RSUs") of the Issuer. F2 · balance_after: Includes 24,374 restricted stock units. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 21:13 UTC | CODEXIS, INC. CDXS · Entity 6428 | SaleCommon Stock | 6,239 | $2.51 | $15,628.70 |
DisclosureSEC source: 0001610717-25-000362 · form4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,636 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to Restricted Stock Units ("RSUs") of the Issuer. F2 · balance_after: Includes 33,333 restricted stock units. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 22:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001610717-25-000224 · form4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 01:17 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 161,250 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0000905148-25-000440 · form4.xml · derivative · entry 2 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,250 Underlying: Common Stock · 161,250 shares Expires 2035-02-05 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 01:17 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 26,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000440 · form4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,875 F1 · shares: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| October 10, 2024 Filed Oct 10, 2024 22:20 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0000905148-24-002705 · form4.xml · derivative · entry 2 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-10-10 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of September 30, 2024, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| October 10, 2024 Filed Oct 10, 2024 22:20 UTC | CODEXIS, INC. CDXS · Entity 6428 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-002705 · form4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 22:54 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 114,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001610717-24-000293 · form4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,000 Underlying: Common Stock · 114,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/3rd of the total number of shares on the one year anniversary of June 4, 2024 and 1/36th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:02 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001610717-24-000088 · form4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2034-02-20 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from February 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:25 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001209191-22-040229 · doc4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2031-06-02 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1 · derivative.exercise_date: The options vest at the rate of 2.778% monthly, beginning on the one-month anniversary of the grant date, with 100% vested on the three-year anniversary of the grant date, subject to the provision of service by the Reporting Person to the Issuer on each vesting date. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 16:05 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantEmployee Stock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-22-005885 · doc4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: 1/48th of the total stock option will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 28, 2022, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 16:02 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantEmployee Stock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001209191-21-064440 · doc4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2031-11-11 F1 · derivative.exercise_date: Fifty percent of the stock option shall be fully vested and exercisable on the first anniversary of the vesting commencement date, November 11, 2022, and thereafter twenty-five percent of the stock option shall vest on each May 11, 2023, and November 11, 2023. Read SEC document |
| September 22, 2021 Filed Sep 22, 2021 21:30 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | PurchaseCommon Stock | 10,300 | $8.10 | $83,430.00 |
DisclosureSEC source: 0001209191-21-057342 · doc4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 19,215 F1 · ownership.nature: Shares indirectly held by Georgia Leigh Erbez Charles Schwab & Co Inc Cust IRA Contributory ("Georgia Erbez IRA Contributory"). The Reporting Person has beneficial ownership over these shares held by Georgia Erbez IRA Contributory. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 10:48 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001209191-21-038129 · doc4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: The options vest at the rate of 2.778% monthly, beginning on the one-month anniversary of the grant date, with 100% vested on the three-year anniversary of the grant date, subject to the provision of service by the Reporting Person to the Issuer on each vesting date. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 08:31 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-21-011626 · doc4.xml · derivative · entry 4 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,908 Underlying: Common Stock · 25,000 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 29, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 08:31 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 25,000 | $2.12 | $53,000.00 |
DisclosureSEC source: 0001209191-21-011626 · doc4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 19:55 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantEmployee Stock Option (right to buy) · Derivative | 72,000 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0001209191-21-006304 · doc4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares subject to the option on February 28, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments at the end of each month, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 18:36 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | PurchaseCommon Stock | 5,000 | $11.40 | $57,000.00 |
DisclosureSEC source: 0001209191-20-047804 · doc4.xml · nonDerivative · entry 2 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,915 F1 · ownership.nature: Shares indirectly held by Georgia Leigh Erbez Charles Schwab & Co Inc Cust IRA Contributory ("Georgia Erbez IRA Contributory"). The Reporting Person has beneficial ownership over these shares held by Georgia Erbez IRA Contributory. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 18:36 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | PurchaseCommon Stock | 2,098 | $11.60 | $24,336.80 |
DisclosureSEC source: 0001209191-20-047804 · doc4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,915 F1 · ownership.nature: Shares indirectly held by Georgia Leigh Erbez Charles Schwab & Co Inc Cust IRA Contributory ("Georgia Erbez IRA Contributory"). The Reporting Person has beneficial ownership over these shares held by Georgia Erbez IRA Contributory. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 08:32 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | PurchaseCommon Stock | 1,817 | $10.92 | $19,841.64 |
DisclosureSEC source: 0001209191-20-044576 · doc4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,817 F1 · ownership.nature: Shares indirectly held by Georgia Leigh Erbez Charles Schwab & Co Inc Cust IRA Contributory ("Georgia Erbez IRA Contributory"). The Reporting Person has beneficial ownership over these shares held by Georgia Erbez IRA Contributory. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 20:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantEmployee Stock Option (right to buy) · Derivative | 52,160 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001209191-20-006703 · doc4.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,160 Underlying: Common Stock · 52,160 shares Expires 2030-01-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares subject to the option on February 29, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments at the end of each month, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 08:34 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | PurchaseCommon Stock | 6,700 | $14.09 | $94,417.74 |
DisclosureSEC source: 0001209191-20-004581 · doc4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,700 F1 · ownership.nature: Shares indirectly held by David Milan Erbez Charles Schwab & Co Inc Cust IRA Contributory ("Erbez IRA Contributory"). The Reporting Person has beneficial ownership over these shares held by Erbez IRA Contributory. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 16:41 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 47,292 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-059489 · doc4.xml · derivative · entry 2 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,908 Underlying: Common Stock · 47,292 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 29, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 16:41 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 47,292 | $2.12 | $100,259.04 |
DisclosureSEC source: 0001209191-19-059489 · doc4.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 25, 2017 20:55 UTC | Zosano Pharma Corp ZSAN · Entity 12518 | PurchaseCommon Stock | 68,000 | $1.32 | $89,760.00 |
DisclosureSEC source: 0001587221-17-000018 · edgar.xml · nonDerivative · entry 1 Erbez Georgia · CIK 0001557930 · CFO and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,750 Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 16:29 UTC | Zosano Pharma Corp ZSAN · Entity 12518 | GrantStock Option (right to buy) · Derivative | 252,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001557930-16-000010 · edgar.xml · derivative · entry 1 Erbez Georgia · CIK 0001557930 · CBO and Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,000 Underlying: Common Stock · 252,000 shares Expires 2026-09-07 F1 · derivative.exercise_date: The stock option becomes exercisable on the first anniversary of the date of grant for 25% of the total number of option shares and becomes exercisable on the corresponding day of each month thereafter for an additional 1/48th of the total number of option shares, so that the stock option is fully vested on the fourth anniversary of the date of grant; provided, however, that 25% of the total option shares (in addition to any then-vested option shares) shall vest if the holder is terminated without cause or resigns for good reason (as these terms are defined in the holder's employment agreement); provided, further, that 100% of any then unvested option shares shall vest if the holder is terminated without cause or resigns for good reason within one year after a change in control (as defined in the holder's employment agreement). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.